Reviewer's report

Title: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

Version: 1 Date: 12 August 2009

Reviewer: JL Pujol

Reviewer's report:

In this study the authors have evaluated cost effectiveness of two drugs that have similar indication as second line chemotherapy in patients who failed to platinum based chemotherapy. The main finding is that pemetrexed is cost effective comparing with docetaxel and according to a € 30000/QALY threshold.

This is a well-written manuscript reporting a well-conducted analysis. The topic is of interest and the conclusion is supported by the Markov model analysis.

My sole remark would has been : why erlotinib has not been also analyzed inasmuch as there is a similar indication in nsclc?

I would recommend acceptance with minor corrections.